Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044618 | 1.00 | PARP1 (0.34) | PARP1PARP3HDAC4ATM | |
| SCHEMBL5043749 | 0.94 | ATM (0.32) | HDAC4ATM | |
| SCHEMBL14011669 | 0.94 | ATM (0.32) | HDAC4ATM | |
| SCHEMBL5043744 | 0.94 | ATM (0.32) | HDAC4ATM | |
| SCHEMBL4214661 | 0.93 | FFAR1 (0.33) | — | |
| SCHEMBL4214663 | 0.93 | FFAR1 (0.33) | — | |
| SCHEMBL4045700 | 0.92 | PKM (0.34) | — | |
| SCHEMBL4045702 | 0.92 | PKM (0.34) | — | |
| SCHEMBL5047027 | 0.89 | POLB (0.34) | PARP1PARP3HDAC4 | |
| SCHEMBL5047026 | 0.89 | POLB (0.34) | PARP1PARP3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678157-A4 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456288-B2 | Heterocyclic compounds and methods of making and using thereof | REDDY US THERAPEUTICS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1678157-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | Reddy US Therapeutics, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-02 | — | — | US | disclosed |
| WO-2005042712-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119269-A1 | Heterocyclic compounds and methods of making and using thereof | PYGM, MYLK, HMOX1 | PARP1 1223/4885PARP3 2363/4885HDAC4 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.